

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

Panc02

RRID:CVCL_D627

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C067, RRID:CVCL_D627

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_D627

Proper Citation: Ubigen Cat# YC-C067, RRID:CVCL_D627

Description: Cell line Panc02 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse pancreatic ductal adenocarcinoma

Defining Citation: [PMID:6692374](#), [PMID:11558631](#), [PMID:20805420](#), [PMID:21720167](#), [PMID:22208613](#), [PMID:24278292](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Panc02

Synonyms: Panc-02, Panc 02, Pan02, Pan-02, PAN 02, Panc02-H0

Cross References: BTO:BTO_0005175, CCRID:1101MOU-PUMC000446, ChEMBL-Cells:ChEMBL4483161, ChEMBL-Targets:ChEMBL4483283, CLS:300501, NCI-DTP:Pan 02, PubChem_Cell_line:CVCL_D627, Ubigen:YC-C067, Wikidata:Q54937552

ID: CVCL_D627

Vendor: Ubigen

Catalog Number: YC-C067

Record Creation Time: 20250130T072603+0000

Record Last Update: 20260905T184106+0000

Ratings and Alerts

No rating or validation information has been found for Panc02.

No alerts have been found for Panc02.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 187 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gao M, et al. (2026) Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model. *Molecular cancer therapeutics*, 25(3), 469.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. *Communications biology*, 9(1).

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. *Cell reports. Medicine*, 7(2), 102613.

Pan Z, et al. (2026) OCIAD2-IQGAP1 interaction promotes pancreatic cancer progression by suppressing oxidative stress and mitochondria-mediated apoptosis. *Cellular signalling*, 138, 112217.

Li G, et al. (2026) Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation. *Cancer research*, 86(10), 2327.

Humer D, et al. (2026) NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors. *Nature communications*, 17(1).

Jin Y, et al. (2026) Synergistic Enhancement of Immunogenic Cell Death Through Photothermal/Photodynamic Effects via Complex Nanoenzymes for Pancreatic Cancer Therapy. *Advanced healthcare materials*, 15(23), e05709.

Yamazaki T, et al. (2026) WT1-Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e24323.

Kobayashi H, et al. (2026) Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. *Cancer research*, 86(8), 1883.

Zhang Y, et al. (2026) Dual blockade of PD-1 and NKG2A prevents NK cell senescence and reprograms the immunosuppressive microenvironment in pancreatic cancer. *Cell*

reports, 45(7), 117583.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. *iScience*, 29(7), 116500.

Zhao Y, et al. (2026) Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation. *EMBO molecular medicine*, 18(6), 2213.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of ?-PD-1 by altering the intestinal microbiome and PGD2 content. *Gut microbes*, 17(1), 2447821.

Aboalela MA, et al. (2025) Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. *Cancer immunology, immunotherapy : CII*, 74(7), 202.

Neitzel LR, et al. (2025) Inhibition of GPR68 induces ferroptosis and radiosensitivity in diverse cancer cell types. *Scientific reports*, 15(1), 4074.

Nasti A, et al. (2025) Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer. *Molecular oncology*, 19(5), 1452.

Li X, et al. (2025) Plakophilin 3 drives acinar cell transformation and promotes cancer initiation and progression in pancreas. *Cell reports*, 44(11), 116487.

Wei Q, et al. (2025) Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3. *iScience*, 28(3), 111931.

Lai X, et al. (2025) Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e20625.

Zhao J, et al. (2025) Targeting plasticity in the pyrimidine synthesis pathway potentiates macrophage-mediated phagocytosis in pancreatic cancer models. *The Journal of clinical investigation*, 135(22).